As Pfizer Vaccine Gets Emergency Approval, Experts Say It’s Time to Face Challenges (International Business Times IBT)

Farhana Nakhooda and Gary Chua spoke to IBTImes Singapore about the challenges ahead and how world governments can solve vaccine-related issues.

By Bhaswati Guha Majumder | Dec. 12, 2020

Days after the UK became the first country to begin mass vaccination using Pfizer-BioNTech COVID-19 shot, the Food and Drug Administration (FDA) in the US has authorized the vaccine for emergency use and called the announcement a “significant milestone”.

The vaccine has also received regulatory approval in Canada, Bahrain and Saudi Arabia. But according to experts, challenges are not over until people all around receive a vaccine within time and the clock is ticking.

Farhana Nakhooda, Senior Vice President, Healthcare & Life Sciences (Asia Pacific), Health Catalyst, and Gary Chua, Chief Operating Officer, Asia Pacific and Japan, Syniti, explained the issues with these current vaccines and what governments around the world should do to ensure the safety of the citizens from novel Coronavirus infection…